In a report released yesterday, Ken Cacciatore from Cowen & Co. maintained a Buy rating on Aurinia Pharmaceuticals (AUPH – Research Report), with a price target of $30.00. The company's shares closed last Tuesday at $11.27, close to its 52-week low of $8.86. According to TipRanks.com, Cacciatore is a 1-star analyst with an average return of -2.7% and a 39.7% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Molecular Partners AG, Jazz Pharmaceuticals, and Aerie Pharma. Currently, the analyst consensus on Aurinia Pharmaceuticals is a Strong Buy with an average price target of $24.44, implying a 154.3% upside from current levels.
https://www.tipranks.com/news/blurbs/cowen-co-thinks-aurinia-pharmaceuticals-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral